Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

10x Genomics ebitda from 2018 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

10x Genomics EBITDA 2018-2025 | TXG

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

10x Genomics ebitda from 2018 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Veeva Systems (VEEV)	$35.1B
Tempus AI (TEM)	$7B
Hims & Hers Health (HIMS)	$6B
Inspire Medical Systems (INSP)	$4.5B
IRhythm Technologies (IRTC)	$3.2B
Privia Health (PRVA)	$2.9B
Schrodinger (SDGR)	$1.9B
Clover Health Investments (CLOV)	$1.8B
Enovis (ENOV)	$1.8B
Omnicell (OMCL)	$1.4B
Phreesia (PHR)	$1.4B
Azenta (AZTA)	$1.2B
Butterfly Network (BFLY)	$568M
Fulgent Genetics (FLGT)	$551M
Talkspace (TALK)	$450M
Veradigm (MDRX)	$449M
Standard BioTools (LAB)	$440M
TruBridge (TBRG)	$363M
Claritev (CTEV)	$325M
Health Catalyst (HCAT)	$270M
Nyxoah SA (NYXH)	$206M
SOPHiA GENETICS SA (SOPH)	$189M
Pulmonx (LUNG)	$182M
American Well (AMWL)	$109M
EUDA Health Holdings (EUDA)	$100M
Retrieve Medical Holdings (RMHI)	$82M
MDxHealth SA (MDXH)	$76M
P3 Health Partners (PIII)	$66M
111 (YI)	$64M
CareCloud (CCLD)	$60M